Contrary to the prevailing professional opinion of the past few decades, recent experimental and clinical data support the fact that protein replacement therapy by allogeneic blood and marrow transplantation is not limited to freely diff usible molecules such as enzymes, but also large structural proteins such as collagens. A prime example is the cross-correction of type VII collagen defi ciency in generalised severe recessive dystrophic epidermolysis bullosa, in which blood and marrow transplantation can attenuate the mucocutaneous manifestations of the disease and improve patients' quality of life. Although allogeneic blood and marrow transplantation can improve the integrity of the skin and mucous membranes, today's accomplishments are only the fi rst steps on the long pathway to cure. Future strategies will be built on the lessons learned from these fi rst transplant studies.
Introduction
Dystrophic epidermolysis bullosa is a group of heritable mechanobullous skin diseases typifi ed by skin fragility, blister formation, and scarring. The most severe forms of the disease are characterised by mutilating scarring, blisters covering large proportions of the body surface, and, later in the disease course, mitten deformities, joint contractures, oesophageal strictures, corneal erosions, chronic cutaneous infections, and aggressive squamous cell carcinoma. [1] [2] [3] Children and adults with recessive dystrophic epidermolysis bullosa face a life of pain and a high risk of developing squamous cell carcinoma, which can occur as early as 13 years of age. Of the patients who survive to reach 40 years of age, 50% have this cancer. Nearly all patients with dystrophic epidermolysis bullosa and squamous cell carcinoma die from metastatic disease. Patients with severe dystrophic epidermolysis bullosa have profound physical disabilities, and daily activities (eg, going to the toilet, feeding, bathing, and walking) are major challenges. Children with the disease need round-the-clock daily care, and the quality of life of patients tends to decline with age.
Pathophysiology
Type VII collagen (C7) is synthesised by both human keratinocytes and fi broblasts. The protein is secreted within the basement membrane zone that lies between the epidermis and dermis of the skin. C7 is the major component of anchoring fi brils, which are necessary for normal epidermal-dermal adherence. Genetic defects in the C7 gene, COL7A1, lead to recessive dystrophic epidermolysis bullosa. Ultrastructurally abnormal morph ology and the absence or scarcity of anchoring fi brils result in extreme skin fragility caused by cleavage and detachment of the sublamina densa from the underlying dermis (fi gure 1). Dystrophic epidermolysis bullosa can be inherited as an autosomal dominant or autosomal recessive disease, with blisters and scarring present at birth or shortly afterwards. The blisters in the neonate often cover the whole body, including the oral and oesophageal mucosa, and persist throughout life.
Wound healing and chronic skin infections
After injury, healthy skin regenerates with remarkable effi ciency. All layers of the skin and its cellular compartments are engaged in this robust and carefully regulated process. Recent accumulating experimental and clinical experience, partly from cellular transplantation studies in recessive dystrophic epidermolysis bullosa, provides evi dence that extracutaneous cells and factors are also operational in skin repair, thus increasing our understanding of the underlying molecular and cellular mech an isms responsible for the maintenance of skin integrity.
Wound care in people with epidermolysis bullosa poses unique challenges. Highly personalised treatment plans are necessary because of variations in clinical severity, pathogenicity of the bacterial and fungal organisms present, degree of skin involvement, and the patient's age. Furthermore, as patients get older, they have a higher risk of colonisation with antibiotic-resistant bacteria, such as meticillin-resistant Staphylococcus aureus and pan-resistant Pseudomonas aeruginosa. The implications for wound healing depend on the bacterial load and virulence. Whereas contamination refers to smaller bacterial loads with little eff ect on wound healing, critical colonisation occurs when bacterial proliferation causes local damage and wound healing is prevented. 4 In this situation, chronic, non-healing wounds occur, despite intact epithelial repair mechanisms. In some cases, these wounds are due to the development of bacterial biofi lms-a state in which bacteria and secreted extracellular substances adhere to the wound bed and become almost impenetrable to antibiotic treatment. Such wounds are debilitating and potentially life-threatening. Treatment strategies for the removal of biofi lms include topical and systemic antibiotics, silver dressings, and debridement. 
Blood and marrow transplantation

Potential of blood and marrow stem cells
The biology of stem-cell transplantation has been fortu nate in its rich history of constant innovation and adaptation, and in its ability to transfer experimental fi ndings directly into patients with life-threatening diseases. Haemopoietic stem-cell transplantation, the prototypical stem-cell therapy, has been a life-saving approach for people with more than 70 diff erent haem a tological diseases for the past 45 years. 6 Furthermore, the discovery that a few blood or bone marrow stem cells taken from a donor can give rise to a fully functional lympho-haemopoietic system in the recipient enabled therapy for some equally fatal non-malignant disorders, such as genetic enzymopathies. 7 This treatment eff ect is due to the ability of donor cells to secrete an enzyme (such as lysosomal hydrolase in mucopoly saccharidoses) and the ability of the recipient cells to take it up even when they are themselves defi cient. Every year, more than 50 000 people now receive haemopoietic stem-cell trans plantation for various, otherwise fatal, malignant and non-malignant disorders. 8 Successful cell and tissue therapies have been mostly confi ned to the repair of the same tissue, such as when bone marrow or umbilical cord blood as a source of haemopoietic stem cells is transplanted into people with lympho-haemopoietic disorders, or similarly when skin grafts are used to replace skin damaged or lost by burns, trauma, or surgery. However, two notable exceptions are that bone marrow can be used to treat the bone disorder osteogenesis imperfecta 9 and the skin disease recessive dystrophic epidermolysis bullosa. 10 The fascinating cellular journey from blood to skin by virtue of the transplantation of bone marrow is both mechanistically signifi cant and clinically relevant. The pathway of treatment of children with generalised severe recessive dystrophic epidermolysis bullosa, which began with near-complete clinical helplessness, has led to an amelioration of their blistering and pain, and improvement to their quality of life.
Repurposing of blood and bone marrow
The problem
The pain that people with recessive dystrophic epidermolysis bullosa endure is often overwhelming, and the consequences of the disease are tragic. Motivated by the suff ering of the patients and despair of their families, the progress achieved in skin biology applied to pre clinical approaches has been equally extraordinary.
Several new treatments that target wounds in the disease have been developed, including local cell therapy with skin fi broblasts 11, 12 and mesenchymal stem or stromal cells, 13 gene therapy with gammaretroviral 14 or lentiviral vectors, [15] [16] [17] and C7 protein replacement therapy. [18] [19] [20] These innovations emanated from decades of preclinical mole cular and cellular studies by highly motivated teams worldwide, 3, 12, [21] [22] [23] [24] [25] [26] [27] and the commitment of both national funding organisations and patient support groups.
Despite the unforgettable appearance of a child with recessive dystrophic epidermolysis bullosa, the pathological process of generalised severe disease is best under stood in its entirety, with several external and internal organ systems being aff ected (cutaneous and gastro intestinal) and whole body responses (such as compromised nutrition, anaemia, pruritus, chronic infl am mation, and local and systemic infections) ampli fy ing the injury of the underlying C7 defi ciency.
There fore, as an alternative to local gene, cell, and protein therapies, we sought systemic and possibly permanent cross -cor rection of C7 in the extracellular matrix with durable trans plantation of self-renewing blood and marrow stem cells.
Proof of concept
To investigate this idea, we transplanted congenic wildtype bone marrow cells (among a range of other stem-cell types) into neonatal mice with a targeted disruption of the Col7a1 gene 28 that results in widespread blistering and early death because of the absence of C7 expression. We hypothesised that a stem-cell population existed in bone marrow that homed to injured skin close to the dermalepidermal junction and produced cellular progeny that secreted wild-type C7 protein where it was needed. Although various non-haemopoietic and haemopoietic cell populations from bone marrow did not successfully correct the disease, it turned out that an infusion of highly purifi ed bone marrow progenitors (CD150+ CD48-cells) 29 migrated to injured skin and secreted C7. Anchoring fi brils were partly restored and blisters on paws healed, 30 whereas untreated aff ected pups died within 14 days.
Thus, donor cells capable of both secreting C7 and homing to the injured mucocutaneous membranes led to part correction of the disease phenotype. This functional correction of C7 was done in a mouse model of human recessive dystrophic epidermolysis bullosa; and this achievement, along with data from Chino and colleagues 
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See Online for video that also showed similar eff ects with prenatal CD90-depleted bone marrow (in the absence of any other curative approach for severe disease), led us to examine the safety and effi cacy of allogeneic blood and marrow transplantation as a treatment for children with the most severe forms of the illness.
First-in-human clinical trial
So far, only the results for the fi rst seven patients have been reported in the scientifi c literature. Here, we provide a general summary of our experience so far. This fi rst clinical trial 10 of systemic cellular therapy for a genodermatosis showed that donor cells home to injured skin and do so in unexpectedly high numbers, expression of C7 is increased and sustained for many years after blood and marrow transplantation, and anchoring fi brils gradually appear and increase in number. Clinically, nearly all patients have experienced some improvement in maintenance of overall skin integrity (fi gure 2).
To provide unequivocal proof for this outcome is challenging. Serial whole-body photography, weighing of dressings used over time, and referencing of parental and patient logs are not objective proof. Without question, fl uctuations in condition occur on a daily and weekly basis. We developed a process to assess skin fragility by exposing small areas of skin to negative pressure and establishing the length of time to blister formation (video). Add itional biochemical and ultrastructural assessments are being incorporated, new devices to assess quality of life from the perspective of the patient and caregivers are being used, and new photographic methods to assess total body wound involvement are being implemented.
Iterative progress
Protocol changes have been made to reduce side-eff ects and improve the speed of recovery. For example, the intensity of the conditioning regimen has been reduced from a combination of busulfan, fl udarabine, and cyclophosphamide to combination therapy with fl udara bine and low doses of cyclophosphamide and radiation (fi gure 3). Of the 20 patients with recessive dystrophic epidermolysis bullosa who received blood and marrow transplantation, fi ve died from disease progression or complications of transplantation, and all those treated with a non-myeloablative regimen are alive. Although the new conditioning regimen is clearly associated with substantially less toxicity, there is an increased chance that mixed chimerism (ie, presence of both host and donor cells) will occur in the blood and marrow com partment, which will occasionally necessitate an inter vention, such as the infusion of donor lymphocytes, to achieve nearly complete chimerism. The eff ect of the mesenchymal stromal cell infusions (fi gure 3) on skin integrity is less clear. Although transient engraftment of mesenchymal stromal cells has been detected in the skin and blood, the incidence of acute graft-versus-host disease has been extraordinarily low so far. Whether something diff erent about the skin in recessive dystrophic epidermolysis bullosa reduces the risk of graft-versus-host disease or whether the presence of mesenchymal stromal cells at the time of blood and marrow transplantation prevents graftversus-host disease is not yet known.
Thus, of the 20 transplant recipients, many, but not all, have signifi cant benefi t from allogeneic blood and marrow transplantation-chronic wounds, once always open and infected, change to acute ones that heal and remain free of blisters; skin is cleared of colonisation with bacteria and fungi; anaemia is resolved or ameliorated; periodical oesophageal dilatations are needed less frequently; and nutrition and growth improve. From these outcomes, we can now think that the specialty can move away from traditional palliative care with its focus on infection and pain control, complex bandaging, and nutritional support. Instead, parents and caretakers could seek more eff ective treatment for severe forms of epidermolysis bullosa when the risks of allogeneic blood and marrow transplantation are justifi able. 32 Nonetheless, in none of the patients has all the skin and mucosal lesions healed, none has had all dressings removed, and none has achieved an entirely normal number and structure of anchoring fi brils. Importantly, this situation is similar to that with other genetic disorders treatable with blood and marrow transplantation, such as mucopolysaccharidosis type I (Hurler syndrome), in which the fatal natural history of the disease is averted but not all disease manifestations are eliminated. However, results achieved so far provide a strong incentive to improve the treatment, to make it more eff ective and less risky.
Clinical fi ndings and lessons learned
Although data are consistent with a model in which donor lympho-haemopoietic cells engraft in a permissive skin niche and provide a continuous source of wild-type cells to mediate skin healing, we need to better understand the biological mechanisms that underlie the potential of the blood and marrow graft to stabilise external and internal mucocutaneous epithelia.
Several fi ndings have off ered guidance. First, in mice, only highly purifi ed haemopoietic stem cells rescued animals with recessive dystrophic epidermolysis bullosa from lethality. In human beings, both haemopoietic and non-haemopoietic donor cells engrafted in human skin after blood and marrow transplant, as evidenced by detection of male donor cells with and without expression of pan-haemopoietic CD45 antigen in the skin of a female transplant recipient (fi gures 4 and 5). Whether these nonhaemopoietic donor-derived cells in the skin are actually derived from the haemopoietic stem cells or from another cell population in the marrow remains unknown. Nonetheless, the skin seems to be able to support other cell populations at high frequency. Second, engraftment is typically higher in the vicinity of active wounds, which suggests that cells home to areas of tissue damage or injury, where local injured cells guide systemic reparative cells to the wounds. Moreover, chimerism in recipient skin is sustained for long periods (at least 5 years so far) and is related to the degree of mucocutaneous improvement.
With this evidence, we can propose a model for consideration. Donor blood and bone marrow (sources that contain both haemopoietic and non-haemopoietic stem cells) home towards the gradient of stress signals or proinfl ammatory factors secreted systemically from active wounds. For example, high-mobility group protein B1, identifi ed in the elegant studies of Tamai and colleagues 33 and Petrof and coworkers, 34 has been shown to cross the vascular wall dermis and locate a permissive environment of skin niches. Once integrated in these so-called docking stations, donor cells secrete C7 chains that homopolymerise in the extracellular matrix 35 and, as they reach the barrier of the basement membrane zone, form anchoring fi brils, resulting in increased skin stability (fi gures 4-6).
Allogeneic blood and marrow transplant is the fi rst form of gene therapy (ie, delivery of wild-type genes-in this case via haemopoietic stem cells from healthy allogeneic donors) in patients with many genetic diseases, such as severe combined immune defi ciency, mucopolysaccharidosis type I, and now epidermolysis bullosa. However, equally relevant to the gene therapy of skin is the rare event of somatic mosaicism. In some patients with recessive dystrophic epidermolysis bullosa, the pathogenic COL7A1 mutation self-corrects by unequal crossover or secondary mutation. [36] [37] [38] [39] This selfcorrection of a single host skin cell results in patches of skin where the pathomechanistic consequences of COL7A1 mutation are reversed: normal or near-normal C7 expression, anchoring fi brils, and skin integrity are achieved. Together, these fi ndings suggest that gene correction of cells resident in the skin can ameliorate the manifestations of the disease. This theory has provided substantial impetus for gene therapy that uses COL7A1 augmentation with viral vectors, 40 corrective transsplicing of mutant COL7A1 RNA, 41 or gene editing in which a specifi c COL7A1 mutation is restored to the wild-type sequence in its natural genomic location. Correction of autologous stem-cell populations could reduce, or perhaps eliminate, the existing need for highdose chemotherapy and immunosuppression for donorhost tolerance induction in the setting of allogeneic blood and marrow transplantation.
Future directions for treatment of recessive dystrophic epidermolysis bullosa
Although substantial improvements have already been made for patients with epidermolysis bullosa undergoing allogeneic blood and marrow transplant, such as the use of a non-myeloablative conditioning regimen (fi gure 3), further advances are necessary. Some promising strategies are listed here.
Gene correction of autologous cells
On the basis of the pioneering work of Mavilio and colleagues in a related form of epidermolysis bullosajunctional epidermolysis bullosa, which is caused by defi ciency of type XVII collagen 43 -at least two groups are pursuing treatment of individual wounds with autologous cells corrected by viral-based ex vivo therapy. These trials have benefi ted from transformative knowledge gained from improved vector designs that aimed to decrease the pro-neoplastic side-eff ects associated with an earlier generation of retroviral vectors in immune defi ciencies (eg, X-linked severe combined immune defi ciency, Wiscott-Aldrich syndrome, and chronic granulomatous disease). 44, 45 The problem of an autonomous so-called selfi sh transgene 46, 47 delivered by a viral vector, however, can be circumvented, in theory, by gene editing. 40 Such gene repair is initiated by binding and cleaving of DNA close to the site of the targeted gene mutation (with a hybrid synthetic molecule such as zinc-fi nger nuclease, homing endonuclease, or transcription activator-like eff ector nuclease [TALEN]) 48, 49 and completed by homologous recombination between exogenously provided wildtype COL7A1 sequence and mutant COL7A1 DNA. We have recently used gene editing to permanently change a pathogenic mutation in COL7A1 to the wild-type sequence, which is, to our knowledge, the fi rst demon stration of TALEN-mediated gene correction of any disease-causing mutation within the natural context of the human genome. 42 This work was undertaken in dermal fi broblasts, which were then amplifi ed to numbers suffi cient for local therapy (as has been done with allogeneic fi broblasts). Of note, fi broblasts are probably superior to keratinocytes for local wound therapy in recessive dystrophic epidermolysis bullosa. Both cell types secrete C7 protein, but fi broblasts Figure 6 : Cross-correction for recessive dystrophic epidermolysis bullosa after blood and marrow transplantation Models of (A) healthy skin and (B) skin in recessive dystrophic epidermolysis bullosa. Presence of patches of mutant type VII collagen at the dermal-epidermal junction does not prevent easy separation of the epidermis from the dermis upon minimal trauma. (C) Model of skin repair in recessive dystrophic epidermolysis bullosa after allogeneic blood and marrow transplantation. Presence of donor cells (yellow) in the dermis and epidermis, indicating the presence of haemopoietic (neutrophils and lymphocytes) and non-haemopoietic cells (stromal cells and possibly keratinocytes) of donor origin that have migrated from the blood or bone marrow graft, homed to the injured skin, and secreted wild-type (normal) type VII collagen above and below the dermal-epidermal junction, leading to enhanced integrity of the skin and resistance to trauma. are more robust and can be cultured extensively. However, to extend the eff ect to systemic therapy, engraftable geneedited stem cells would be needed. Haemopoietic stem cells might, of course, not be the ideal cell type for systemic therapy, but we have yet to identify another population of stem cells (presumably epidermal or mesenchymal) that are capable of long-term engraftment in injured skin after intravenous ad minis tration. As an alternative to the challenging transgenesis of haemopoietic stem cells, several groups have pursued an indirect pathway by reprogramming dermal fi broblasts into pluripotent cells (which function much like embryonic stem cells), termed induced pluripotent stem (iPS) cells. 50, 51 iPS cells are engineered stem cells that have the potential to develop into almost any cell type in the body. For that reason, they have become a popular device for the investigation of tissue formation in health and disease, early stages of development, and so-called disease in a dish (to substitute, in part, for clinical testing of drug inter vention strategies with an in-vitro model), all of which are relevant to the biology and treatment of epidermolysis bullosa. 50, 52 As a fi rst example of induced pluripotency in a disorder of the extracellular matrix, we have shown that iPS cells can be generated from skin fi broblasts of patients with recessive dystrophic epiderm olysis bullosa, diff eren tiated into artifi cial skin equivalents and haemopoietic progenitors, and transduced with wild-type COL7A1 to produce C7 protein. 50 Essential iPS cell issues, such as transgene integration-free reprogramming, genomic fi delity, and transplantability, are being investi gated in an eff ort to develop genomically stable, person alised iPS cellderived cellular grafts 51 that are free of con tamination by undiff erentiated cells and are less susceptible to immune rejection after transplantation than are iPS cells made with existing methods. [53] [54] [55] Crucially, the data from iPS cell biology can now facilitate the previously impossible advances in cell therapy for specifi c clinical needs, such as expansion of disease-free cells from autologous gene-corrected cells or cells from skin patches with somatic mosaicism. In theory, personalised iPS cells can provide an inexhaustible supply of progeny cells with dermal and bone marrow phenotypes, [56] [57] [58] applicable-independently or togetherto both the local and systemic treatment of recessive dystrophic epidermolysis bullosa.
The concept of combining drugs to achieve the same goal by diff erent mechanisms has been supported by many examples from oncology and infectious disease medicine. More recently, we hypothesised that the combination of enzyme replacement therapy with haemopoietic stem-cell transplantion for severe forms of mucopolysaccharidosis type I is superior to either modality alone. 59 A similar combination of protein and cellular therapy is conceivable for recessive dystrophic epidermolysis bullosa. An even greater benefi t might be derived from systemic therapy with blood and marrow transplantation combined with local treatment of the remaining wounds that are resistant because of major previous tissue damage and scarring. In principle, this benefi t can be accomplished with autologous genecorrected fi broblasts (local therapy) and blood and marrow transplantation (systemic lifelong therapy), oreven more imminently-with allogeneic fi broblasts, keratinocytes, or mesenchymal stromal cells from the donor used for local injection in an engrafted recipient of blood and marrow transplantation. In the setting of either matched sibling or unrelated donor, the recipient would be expected to perceive the locally injected cells as self. Thus, the persistence of the cells in and around wounds will probably extend beyond the time observed after injection of allogeneic fi broblasts in patients without previous blood and marrow transplantation, 11, 12 and result in superior clinical benefi t (fi gure 7).
From bedside to bench: new hypotheses
The goal of innovative clinical trials in recessive dystrophic epidermolysis bullosa is to alleviate the suff ering caused by this progressively debilitating disease. As is the case for several rare disorders, changes in the practice of medicine for recessive dystrophic epidermolysis bullosa can also have major implications for much more common affl ictions, such as thermal or chemical burns.
To bring about further improvements, we need to carefully evaluate each patient's response in the quest to understand the mechanisms underlying the disease and its response to treatment.
One of the main challenges is to understand the eff ect of donor cells on upregulation of mutant versus wild-type C7. New C7 was expressed in the vicinity of donor cells at the skin basal membrane zone in mice with recessive dystrophic epidermolysis bullosa that were genetically unable to express any endogenous C7; 28 however, in several human recipients with residual expression of mutant C7 before blood and marrow transplantation we have recorded increased total C7 and clinical improvement afterwards, even when detectable donor cells are absent in the skin. 10, 60 Microchimerism could be operational in that donor cells are merely below the detection limit of the chimerism assays (PCR for a variable number of tandem repeats). Another possibility is that expression of COL7A1 gene is somehow enhanced by the chemotherapy used in the conditioning regimen before allogeneic cell infusion or immunosuppression, but this eff ect would be expected to be transient. By contrast, in some cases, a sustained benefi t has been recorded over several years.
Intriguing data from McGrath's group suggest that local infl ammation induces donor cells to secrete factors (such as heparin-binding epidermal growth factor-like growth factor) that can increase C7 protein concentrations in recipients' skin cells in the murine model of epidermolysis bullosa. 61 Allogeneic cells might also be able to boost the endogenous regenerative capacity of damaged skin through non-C7-based mechanisms. 62 The preferential deposit of C7 protein in the skin and wounds in recessive dystrophic epidermolysis bullosa after systemic appli cation 19 supports not only the role of C7 in wound closure by an increase in keratinocyte mobility and re-epithelialisation, but also the existence of a robust and specifi c homing mechanism that mediates skin repair in the disease.
These two mechanisms (secretion of fully functional C7 from donor cells and partly functional C7 from primed recipient cells) might indeed operate in concert. 25, [63] [64] [65] However, importantly, the sum of direct and indirect release of C7 is not simple and might not be always benign. 12, 66 Some mutations known to cause dominant dystrophic epidermolysis bullosa also occur in recessive disease. Therefore, overexpression of recipient's mutant C7 might act in a dominant negative way when homotrimerised with donor (wild-type) C7. Alternatively, mutant wild-type anchoring fi bril hybrids can be at least partly functional (consistent with our fi nding of rudimentary anchoring fi brils after blood and marrow transplant) or function as scaff olds for assembly of the triple helices of C7 (we owe this latter idea to John A McGrath, King's College, London, UK).
Additionally, donor cells might mediate increased expression of other skin proteins relevant to skin adhesion, such as laminin 322 or fi bronectin. This process could result in improved stability of the skin and a decrease in disfi guring skin fi brosis, even when the concentration of C7 is low and by itself inadequate to prevent blistering. Finally, the combined expression of these compensatory proteins could be key to the creation of a so-called educational gate for entry of donor cells to permissive niches in wounded skin. 67 Another challenge is that injury is the key to homing to skin. Skin is a dynamic, constantly changing organ with high turnover of haemopoietic cells, which are involved in skin immunity, integrity maintenance, and healing of injury. 68 The groups of Socie 69 and Storek 70 have shown that transplanted bone marrow cells can be detected in skin and mucosa (up to 5·5% donor cells, includ ing donorderived keratinocytes in patients with skin graft-versushost disease). Moreover, the work of Krause's team 71 suggested that bone marrow contains epidermal progenitors. The cell fate of such cells from systemic circulation depends on their proliferation potential, permissive ness of the skin niche, and local cell-cell metabolic wiring. Taken together with several examples of context similarities in the niche regulation of the skin, thymus, and bone marrow, [72] [73] [74] [75] [76] [77] [78] [79] these fi ndings support a tentative model of homing, engraftment, and functional integration of blood and bone marrow donor cells in the injured skin of patients with recessive dystrophic epidermolysis bullosa who have received a transplant (fi gure 6).
Conclusions
Data from innovative clinical trials are never as clear as we would like them to be. In some patients, the effi cacy has been incomplete, and in all-even those with a very favourable increase in quality of life-long-term followup with quantitative scoring instruments for severity, pain, itching, disability, and cost of care will be needed to ascertain the durability of the initial clinical benefi t. 80 Fortunately, several blood and marrow transplant recipients from the initial clinical trial have sustained dramatically improved skin integrity and quality of life up to 5 years after transplantation.
Although the idea of allogeneic blood and marrow transplantation for recessive dystrophic epidermolysis bullosa sparked controversy and excitement in equal measure, an increasing amount of data support a conclusion that systemic therapy with bone marrow and umbilical cord blood cells for a genodermatosis is possible, and that it can ameliorate the acute lifethreatening features of generalised severe disease. Advances in bioengineered skin, cellular reprogramming, graft engineering (eg, identifi cation of cells capable of both homing to injured skin and secreting C7), 33 and the convergence of cellular and gene therapy are poised to go further in changing the natural history of this disease.
Perhaps it is also instructive to think about how this work began. The use of stem cells and their potential power to replace diseased and damaged tissues was originally developed by haematologists. Even now, despite all the work with stem cells for many diseases, the only proven curative stem-cell therapy has been haemopoietic stem-cell transplantation for the treatment of high-risk leukaemia, lymphoma, and various nonmalignant diseases of the lymphohaemopoietic system, such as aplastic anaemia and severe combined immune defi ciency. Moreover, blood and marrow transplant physicians are familiar with off ering very high-risk treatments, especially for diseases that themselves are associated with a high risk of death.
Louis Pasteur once said that in the fi elds of observation chance favours only the prepared mind. 81 We began by speculating which stem cells were needed for the repair of this disease. The original hypothesis that multipotent stem cells or epidermal stem cells would correct the disease proved to be incorrect. When bone-marrow-derived stem cells were shown to be able to ameliorate recessive dystrophic epidermolysis bullosa, this fi nding led to new hypotheses that were not bound to any single preconceived idea. Did circulating leucocytes secrete suffi cient C7 to promote the integrity of the dermal-epidermal junction in the disorder? Did a non-haemopoietic stem cell in the bone marrow home to wounds and engraft in the skin?
Few overnight successes occur in medicine, but the fi rst clinical trials have shown a new treatment with substantial benefi t. Lessons have been learned and the treatment and research have progressed with improved support and funding. Patients and families have renewed hope that one day the whole person, not just a patch of skin, could be cured.
